Cancer Res Treat.  2013 Dec;45(4):303-312.

Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients

• Kim DH
• Lee YY
• Shin US
• Moon SM

Abstract

PURPOSE
Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients.
MATERIALS AND METHODS
In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests.
RESULTS
In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively.
CONCLUSION
Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.

Keyword

Colorectal neoplasms; Human influenza; Influenza vaccines; Hemagglutination inhibition tests

MeSH Terms

Cohort Studies
Colorectal Neoplasms*
Hemagglutination Inhibition Tests
Humans
Immunocompromised Host
Influenza Vaccines*
Influenza, Human*
Korea
Mortality
Seasons
Vaccination
Influenza Vaccines

Figure

• 

  Fig. 1 Linear regression analysis between age of subjects and their hemagglutination inhibition (HI) titer.

• 

  Fig. 2 Linear regression analysis between total chemotherapy duration and their hemagglutination inhibition (HI) titer.

Reference

1. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. J Infect Dis. 2006; 194(Suppl 2):S133–S138. PMID: 17163386.

2. Ljungman P, Andersson J, Aschan J, Barkholt L, Ehrnst A, Johansson M, et al. Influenza A in immunocompromised patients. Clin Infect Dis. 1993; 17:244–247. PMID: 8399875.

3. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010; 10:521–526. PMID: 20620116.

4. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9:493–504. PMID: 19628174.

5. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. PLoS One. 2011; 6:e29249. PMID: 22216224.

6. Cho BH, Kolasa MS, Messonnier ML. Influenza vaccination coverage rate among high-risk children during the 2002-2003 influenza season. Am J Infect Control. 2008; 36:582–587. PMID: 18926312.

7. Meidani M, Rostami M, Dehghani F. Why coverage of influenza vaccine is not enough in patients receiving chemotherapy? Int J Prev Med. 2011; 2:186–187. PMID: 21811662.

8. Muller D, Nguyen-Van-Tam JS, Szucs TD. Influenza vaccination coverage rates in the UK: a comparison of two monitoring methods during the 2002-2003 and 2003-2004 seasons. Public Health. 2006; 120:1074–1080. PMID: 17027881.

9. Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol. 2003; 21:1161–1166. PMID: 12637485.

10. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O. Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol. 2008; 19:1658. PMID: 18662953.

11. Jung KW, Park S, Won YJ, Kong HJ, Lee JY, Seo HG, et al. Prediction of cancer incidence and mortality in Korea, 2012. Cancer Res Treat. 2012; 44:25–31. PMID: 22500157.

12. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96). London: European Agency for the Evaluation of Medicinal Products;1997.

13. Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, et al. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemother Pharmacol. 2011; 67:111–115. PMID: 20204362.

14. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer. 1999; 80:219–220. PMID: 10389999.

15. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clin Med Res. 2005; 3:214–220. PMID: 16303886.

16. Looijmans-Van den Akker I, Verheij TJ, Buskens E, Nichol KL, Rutten GE, Hak E. Clinical effectiveness of first and repeat influenza vaccination in adult and elderly diabetic patients. Diabetes Care. 2006; 29:1771–1776. PMID: 16873778.

17. Xie H, Jing X, Li X, Lin Z, Plant E, Zoueva O, et al. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLos One. 2011; 6:e16650. PMID: 21304946.

18. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer. 1979; 43:25–30. PMID: 761165.

19. Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr Top Microbiol Immunol. 2009; 333:413–429. PMID: 19768417.

20. Lim J, Eom CS, Kim KH, Kim S, Cho B. Coverage of influenza vaccination among elderly in South Korea: a population based cross sectional analysis of the season 2004-2005. J Korean Geriatr Soc. 2009; 13:215–221.

21. Chisholm JC, Devine T, Charlett A, Pinkerton CR, Zambon M. Response to influenza immunisation during treatment for cancer. Arch Dis Child. 2001; 84:496–500. PMID: 11369567.

22. Gross PA, Lee H, Wolff JA, Hall CB, Minnefore AB, Lazicki ME. Influenza immunization in immunosuppressed children. J Pediatr. 1978; 92:30–35. PMID: 619076.

23. Fox JP, Hall CE, Cooney MK, Foy HM. Influenzavirus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol. 1982; 116:212–227. PMID: 7114033.

24. Wright P. Influenza in the family. N Engl J Med. 2000; 343:1331–1332. PMID: 11058679.